申请人:Janssen Pharmaceutica, N.V.
公开号:US05919788A1
公开(公告)日:1999-07-06
The present invention concerns the compounds of formula ##STR1## the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein the dashed line designates an optional bond; R.sup.1 and R.sup.2 are each independently hydrogen, halogen, C.sub.1-6 alkyl or C.sub.1-6 alkyloxy; R.sup.3 and R.sup.4 are each independently hydrogen, C.sub.1-6 alkyl, phenyl or phenyl substituted with one, two or three substituents selected from halo, hydroxy, nitro, cyano, trifluoromethyl, C.sub.1-6 alkyl, C.sub.1-6 alkyloxy, C.sub.1-6 alkylthio, mercapto, amino, mono- and di(C.sub.1-6 alkyl)-amino, carboxyl, C.sub.1-6 alkyloxycarbonyl and C.sub.1-6 alkylcarbonyl; Alk is C.sub.1-4 alkanediyl; D is a pyrimidinone, piperidone or a benzimidozolidinone; having antipsychotic activity; their preparation, compositions containing them and their use as a medicine.
本发明涉及公式##STR1##的化合物,其药学上可接受的加成盐和立体化学异构体,其中虚线表示可选键;R.sup.1和R.sup.2分别独立地为氢,卤素,C.sub.1-6烷基或C.sub.1-6烷氧基;R.sup.3和R.sup.4分别独立地为氢,C.sub.1-6烷基,苯基或苯基上取代有一个,两个或三个取自卤素,羟基,硝基,氰基,三氟甲基,C.sub.1-6烷基,C.sub.1-6烷氧基,C.sub.1-6烷硫基,巯基,氨基,单和双(C.sub.1-6烷基)-氨基,羧基,C.sub.1-6烷氧羰基和C.sub.1-6烷基羰基的取代基;Alk为C.sub.1-4烷二基;D为嘧啶酮,哌啶酮或苯并咪唑啉酮;具有抗精神病活性;它们的制备,含有它们的组合物以及它们作为药物的用途。